The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients

[11] Zareba W(2016)Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death Circulation 134 635-643

[12] Hall WJ(2014)Factors associated with infection in 200.909 Medicare implantable cardioverter defibrillator implants: results from the National Cardiovascular Registry Circulation 130 1037-1043

[13] Klein H(1998)Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation Am J Cardiol 81 1253-1256

[14] Wilber DJ(2004)Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD Pacing Clin Electrophysiol 27 4-9

[15] Cannom DS(2010)Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter-defibrillator (WCD) Pacing Clin Electrophysiol 33 353-367

[16] Daubert JP(2011)Wearable defibrillator in congenital structural heart disease and inherited arrhythmias Am J Cardiol 108 1632-1638

[17] Higgins SL(2003)Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks Pacing Clin Electrophysiol 26 2016-2022

[18] Brown MW(2008)ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities Heart Rhythm 5 e1-e62

[19] Andrews ML(2015)2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology Eur Heart J 36 2793-2867

[20] Moss AJ(2014)HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or well represented in clinical trials JACC 64 1143-1177

[11] Zareba W(2016)Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death Circulation 134 635-643

[12] Hall WJ(2014)Factors associated with infection in 200.909 Medicare implantable cardioverter defibrillator implants: results from the National Cardiovascular Registry Circulation 130 1037-1043

[13] Klein H(1998)Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation Am J Cardiol 81 1253-1256

[14] Wilber DJ(2004)Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD Pacing Clin Electrophysiol 27 4-9

[15] Cannom DS(2010)Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter-defibrillator (WCD) Pacing Clin Electrophysiol 33 353-367

[16] Daubert JP(2011)Wearable defibrillator in congenital structural heart disease and inherited arrhythmias Am J Cardiol 108 1632-1638

[17] Higgins SL(2003)Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks Pacing Clin Electrophysiol 26 2016-2022

[18] Brown MW(2008)ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities Heart Rhythm 5 e1-e62

[19] Andrews ML(2015)2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology Eur Heart J 36 2793-2867

[20] Moss AJ(2014)HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or well represented in clinical trials JACC 64 1143-1177